RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

There is no fulltext present in this item.

Title:	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics
Author(s):	Best, M.G.; Sol, N.; Kooi, I.; Tannous, J.; Westerman, B.A.; Rustenburg, F.; Schellen, P.; Verschueren, H.; Post, E.; Koster, J.; Ylstra, B.; Ameziane, N.; Dorsman, J.; Smit, E.F.; Verheul, H.M.; Noske, D.P.; Reijneveld, J.C.; Nilsson, R.J.; Tannous, B.A.; Wesseling, P. ; Wurdinger, T.
Publication year:	2015
Source:	Cancer Cell, vol. 28, iss. 5, (2015), pp. 666-676
ISSN:	1535-6108
DOI:	https://doi.org/10.1016/j.ccell.2015.09.018
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/152642
Display more details
Subject:	Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Pathology
Journal title:	Cancer Cell
Volume:	vol. 28
Issue:	iss. 5
Page start:	p. 666
Page end:	p. 676
Abstract:	Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based "liquid biopsies".